Bayer, Janssen’s Xarelto cuts risk of amputation, death
admin 13th November 2017 Uncategorised 0Two new analyses of data from the COMPASS trial show that Bayer and Janssen’s blood thinner Xarelto significant cut the amputation rate for patients with peripheral artery disease and also a 23 percent reduction in deaths in patients with coronary artery disease.
More: Bayer, Janssen’s Xarelto cuts risk of amputation, death
Source: News